Literature DB >> 14711076

Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications.

Elizabeth D Hermsen1, Christopher J Sullivan, John C Rotschafer.   

Abstract

Although the polymyxins seem attractive because of their unique structure and mechanism of action, relatively little is known about this group of antibiotics. Much of the available information is from a different era of medical practice when the manipulation of dosing strategies, or optimization of pharmacodynamic parameters, was not commonplace. Moreover, the more recent information that is available is limited in scope with regards to patient populations and microorganisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14711076     DOI: 10.1016/s0891-5520(03)00058-8

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  27 in total

1.  Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Amy N Schilling; Giao Vo; Samer Kabbara; Andrea L Kwa; Nathan P Wiederhold; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Colistin and rhabdomyolysis: a causative agent or an innocent bystander?

Authors:  Penelope Evagelopoulou; Andreas Katsaros; Pavlos Myrianthefs; Stylianos Karatzas; Eleni Boutzouka; George Fildissis; George Baltopoulos
Journal:  Intensive Care Med       Date:  2007-01-20       Impact factor: 17.440

3.  Identification of a polymyxin synthetase gene cluster of Paenibacillus polymyxa and heterologous expression of the gene in Bacillus subtilis.

Authors:  Soo-Keun Choi; Soo-Young Park; Rumi Kim; Seong-Bin Kim; Choong-Hwan Lee; Jihyun F Kim; Seung-Hwan Park
Journal:  J Bacteriol       Date:  2009-03-20       Impact factor: 3.490

4.  Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis.

Authors:  Pornpan Koomanachai; Cornelia B Landersdorfer; Gong Chen; Hee Ji Lee; Anupop Jitmuang; Somkiat Wasuwattakul; Suchai Sritippayawan; Jian Li; Roger L Nation; Visanu Thamlikitkul
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

5.  Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.

Authors:  Cornelia B Landersdorfer; Tri-Hung Nguyen; Linh Thuy Lieu; Gary Nguyen; Robert J Bischof; Els N Meeusen; Jian Li; Roger L Nation; Michelle P McIntosh
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

6.  Quinolones sensitize gram-negative bacteria to antimicrobial peptides.

Authors:  Miguel A Campos; Pau Morey; José A Bengoechea
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

7.  Clinico-microbiological study of Pseudomonas aeruginosa in wound infections and the detection of metallo-β-lactamase production.

Authors:  Divya Bangera; Suchitra M Shenoy; Dominic Rm Saldanha
Journal:  Int Wound J       Date:  2015-10-30       Impact factor: 3.315

8.  High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma.

Authors:  Tiffany A Thomas; Emily C Broun; Kirsten M Abildskov; Christine J Kubin; Jennifer Horan; Michael T Yin; Serge Cremers
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

9.  Analysis of the networks controlling the antimicrobial-peptide-dependent induction of Klebsiella pneumoniae virulence factors.

Authors:  Enrique Llobet; Miguel A Campos; Paloma Giménez; David Moranta; José A Bengoechea
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

10.  Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock.

Authors:  Suresh Ramasubban; Ayanava Majumdar; Purnendu Sekhar Das
Journal:  Indian J Crit Care Med       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.